ArticleCureus2026
Massive Bilateral Breast Hypertrophy in Pregnancy Due to Gestational Gigantomastia: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational gigantomastia is a very rare disorder characterised by massive, bilateral breast enlargement during pregnancy. Clinically, it is characterised by rapid breast enlargement associated with severe mastodynia, back and shoulder pain, and erythema of the skin. In its most severe forms, it can lead to ulceration, necrosis, haemorrhage, or septicaemia. The underlying pathophysiology is not completely understood, but is thought to be multifactorial, involving hormonal hypersensitivity and autoimmune mechanisms. Histopathological confirmation is necessary for definitive diagnosis because its clinical presentation can closely mimic that of inflammatory breast carcinoma or other malignant neoplasms. We report a case of a 28-year-old primigravida who presented at 24 weeks of gestation with progressive bilateral breast enlargement that reached its maximal extent at 36 weeks and caused significant functional impairment. On clinical examination, there was symmetrical breast hypertrophy with diffuse erythema and a marked peau d'orange appearance. Breast ultrasound revealed glandular hypertrophy with ductal ectasia and marked oedema. No suspicious focal lesions were seen. Hormonal and immunological workup was normal, and skin and glandular biopsy showed benign hyperplasia without atypia. Throughout the pregnancy, conservative management with analgesics and postural support was continued until an uncomplicated vaginal delivery at 39 weeks of gestation. Cabergoline was then administered to suppress lactation. Given the absence of spontaneous regression of the breasts, a multidisciplinary decision was taken to perform a bilateral reduction mammoplasty at 12 months postpartum. This case demonstrates the phenotypic variability of gestational gigantomastia that may present without any preceding breast pathology. In severe cases, surgical treatment (reduction mammoplasty or bilateral mastectomy with delayed reconstruction) is the mainstay of treatment, and bromocriptine is the best-established medical alternative, but with variable success. Coordinated multidisciplinary care is essential to optimise patient outcomes and minimise life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.